Lung cancer
Conditions
Interventions
Intercostal nerve block group:With the patient in the prone position, a low-frequency ultrasound probe was placed next to the spine to identify the ribs from top to bottom, and depending on the interc
Pleural infiltration anaesthesia group:According to the location of the lesion in relation to the pleura, a syringe or puncture needle is selected to anaesthetise the pleura near the lesion, and the s
when it is greater than 3 cm, a 20G or 21G puncture needle (PTC needle) should be used for anaesthesia, which is achieved by measuring the distance from the skin at the site of the punctu
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Signed informed consent and aged =65 years; (2) Pathologically confirmed diagnosis of lung cancer, which is determined to be early stage (AJCC 9th edition ?A, ?B, ?A stage, i.e., the diameter of the tumour is =5cm, and there is no lymph node and distant metastasis) by PET-CT, enhanced CT and other imaging examinations; (3) The tumour is located under the pleura: the edge of the tumour is =10mm away from the rib pleura on the CT lung window image; (4) Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-3; (5) Inability to tolerate or refusal of surgery and radiotherapy; (6) Primary patients who have not received adjuvant therapy other than supportive care; (7) Expected survival of more than 3 months; (8) The treatment process cooperates with the provision of clinicopathological data and imaging data required for the research process, cooperates with the follow-up and agrees to use the test data for subsequent research.
Exclusion criteria
Exclusion criteria: (1) Severe haemorrhage and coagulation disorders, platelets less than 50 x 109/L; (2) Eastern Oncology Collaborative physical status score >3; (3) Severe systemic infection, high fever (>38.5?), skin infection and ulceration at the puncture site; (4) With other malignant tumours or severe multi-organ dysfunction; (5) Expected survival period of less than 3 months; (6) Unable to accept or unable to provide designated means of efficacy assessment such as imaging.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preoperative VAS score;Intraoperative VAS score measurement;VAS score at 24 hours postoperatively;Intraoperative and/or postoperative pain duration, management and eventual improvement;Ablation-related adverse events occurring in the perioperative period; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ablation-related adverse events within 1 month of discharge; | — |
Countries
China
Contacts
Public ContactXiao-guang Li
Beijing Hospital
Outcome results
None listed